References
- 1. Marchio P, Guerra-Ojeda S, Vila JM, et al. Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation. Oxidative Medicine and Cellular Longevity. 2019; Article ID: 8563845.10.1155/2019/8563845663648231354915
- 2. Steven S, Frenis K, Oelze M, et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxid Med Cell Longev. 2019; 2019: 7092151.10.1155/2019/7092151661239931341533
- 3. Leiva Е, Wehinger S, Guzmán L, et al. Role of Oxidized LDL in Atherosclerosis. Hypercholesterolemia. 2015 September; Sekar Ashok Kumar, IntechOpen. Available from: https://www.intechopen.com/books/hypercholesterolemia/role-of-oxidized-ldl-in-atherosclerosis.10.5772/59375
- 4. Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular disease. Crit Rev Clin Lab Sci. 2015; 52(2): 70–85.10.3109/10408363.2014.99206325537066
- 5. Yusoff WNW, Bakar NAA, Muid S, et al. Anti-oxidant activity of HDL using different in vitro assays. Journal of fundamental and applied sciences. 2017; 9(6S): 298–315.10.4314/jfas.v9i6s.24
- 6. Ali KM, Wonnerth A, Huber K, et al. Cardiovascular disease risk reduction by raising HDL cholesterol – current therapies and future opportunities. Br J Pharmacol. 2012; 167(6): 1177–1194.10.1111/j.1476-5381.2012.02081.x350498622725625
- 7. Gao S, Liu J. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. Chronic Dis Transl Med. 2017; 3(2): 89–94.10.1016/j.cdtm.2017.02.008562769829063061
- 8. Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest. 1955; 34(9): 1345–53.10.1172/JCI10318243870513252080
- 9. de Juan-Franco E, Perez A, Ribas V, et al. Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins. Int J Biomed Sci. 2009; 5(4): 402–10.
- 10. Esterbauer H, Striegl G, Puhl H, et al. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989; 6(1): 67–75.10.3109/107157689090734292722022
- 11. Alfaddagh A, Martin SS, Leucker TM, et al. Inflammation and cardiovascular disease: From mechanisms to therapeutics. American Journal of Preventive Cardiology. 2020; 4: 100130.10.1016/j.ajpc.2020.100130831562834327481
- 12. Calfee CS, Delucchi KL, Sinha P, et al. Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med. 2018; 6(9): 691–698.10.1016/S2213-2600(18)30177-2
- 13. Karmaus PWF, Shi M, Perl S, et al. Effects of rosuvastatin on the immune system in healthy volunteers with normal serum cholesterol. JCI Insight. 2019; 4(21): e131530.10.1172/jci.insight.131530694877331573980
- 14. Ivanova EA, Myasoedova VA, Melnichenko AA, et al. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017; 2017: 1273042.10.1155/2017/1273042544112628572872
- 15. Nezami N, Argani H, Safa J, et al. Lovastatin enhances paraoxonase anzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy. Clinical Biochemistry. 2011; 44(2): 165–170.10.1016/j.clinbiochem.2010.10.00620970413
- 16. Thallinger C, Urbauer E, Lackner E, et al. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients. Int J Clin Pharmacol Ther. 2005; 43(12): 551–7.10.5414/CPP43551
- 17. Portal VL, Moriguchi EH, Vieria JL, et al. Comparison of the effect of two HMG CoA reductase inhibitors on LDL susceptibility to oxidation. Arquivos Brasileiros de Cardiologia. 2003; 80(2): 156–161.10.1590/S0066-782X2003000200004
- 18. Pirillo A, Catapano AL. Pitavastatin and HDL: Effects on plasma levels and function(s). Atheroscler Suppl. 2017; 27:e1-e9.10.1016/j.atherosclerosissup.2017.05.00128716185
- 19. Triolo M, Annema W, de Boer JF, et al. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest. 2014; 44(3): 240–8.10.1111/eci.1222624325778
- 20. Parthasarathy S, Raghavamenon A, Garelnabi MO, et al. Oxidized low-density lipoprotein. Methods Mol Biol. 2010; 610: 403–417.10.1007/978-1-60327-029-8_24331535120013192
- 21. Fessler MB, Rose K, Zhang Y, et al. Relationship between serum cholesterol and indices of erythrocytes and platelets in the US population. J Lipid Res. 2013; 54(11): 3177–3188.10.1194/jlr.P037614379362223999863
- 22. Wang X, Yang L, Liu Y, et al. Oxidized low-density lipoprotein (Ox-LDL) impacts on erythrocyte viscoelasticity and its molecular mechanism. Journal of Biomechanics. 2009; 42(14): 2394–2399.10.1016/j.jbiomech.2009.05.02619747680
- 23. Rhoads JP, Major AS. How Oxidized Low-Density Lipoprotein Activates Inflammatory Responses. Crit Rev Immunol. 2018; 38(4): 333–342.10.1615/CritRevImmunol.2018026483652711030806246
- 24. Pirillo A, Norata GD, Catapano AL. LOX-1, Ox-LDL and Atherosclerosis. Mediators of Inflammation. 2013; 152786.10.1155/2013/152786372331823935243
- 25. McCarthy DA, Ranganathan A, Subbaram S, et al. Redox-control of the alarmin, Interleukin-1α. Redox Biol. 2013; 1(1): 218–225.10.1016/j.redox.2013.03.001375769324024155
- 26. Liu T, Zhang L, Joo D, et al. NF-kB signaling in inflammation. Signal Transduction and Targeted Therapy. 2017; 2: 17023.10.1038/sigtrans.2017.23566163329158945
- 27. Tao J, Zhang D, Zhang D, et al. Effect of sodium ferulate on IL-8 expression induced by Ox-LDL in human umbilical vein endothelial cells. Biomedical Research. 2017; 28(5).